ZymoGenetics’ early focus on the development of production systems for recombinant proteins
Business Model:
Revenue: $0
Employees: 201-500
ZymoGenetics was acquired by
Bristol Myers Squibb.
The acquisition happend on 2010-09-08.
Details of the transaction were not public
Address:
City: Seattle
State: Washington
Zip:
Country: United States
ZymoGenetics is focused on the discovery, development, and early manufacture of therapeutic proteins. ZymoGenetics is a fully-integrated research and development organization with a broad range of skills and technologies, including scientific computing, molecular and cellular biology, protein chemistry, antibody generation and engineering, clinical development and operations, regulatory affairs, quality, drug formulation, process development and protein manufacturing.
Contact Phone:
Contact Email:
Listed Exchange:
NASDAQ
IPO Date:
2/1/2002
IPO Valuation:
$540M
Ticker Symbol:
ZGEN
IPO Price:
$12/share
Amount Raised:
$120M
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 6/2008 | Post-IPO Debt | 1 | $100M |
Deerfield Deerfield Deerfield Deerfield |
1/2000 | Funding Round | 1 | - |
Frazier Healthcare Partners Frazier Healthcare Partners |
1/2000 | Funding Round | 1 | - |
Frazier Healthcare Partners Frazier Healthcare Partners |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|